From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out

As FDA prepares for the Critical Path initiative, offices across the agency are expanding the use of the risk-based approach to regulation and applying a quality systems approach to internal operations.

Related Content:

Regulatory/GMP ComplianceProcess ValidationManufacturingQuality SystemsPharmaceutical Technology-07-02-2004

Shining a Light on Junior Pharmaceuticals

Introduction to Pharmaceutical QMM Model: QMM Assessment to Promote Pharmaceutical Operational Excellence

Overhauling the Human Medicines Directive and Regulation